Suguru Mizuno, Kenji Hirano, Hiroyuki Isayama, Takeo Watanabe, Natsuyo Yamamoto, Yousuke Nakai, Naoki Sasahira, Minoru Tada, Masao Omata and Kazuhiko Koike
Abstract
Background:
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease. Medical treatments must be devised to avoid or postpone liver transplantation in PSC patients. No clinical trial has prospectively explored the efficacy of bezafibrate in PSC patients.
Methods:
We conducted a prospective study of 12-week bezafibrate treatment, with pre- and post-treatment observation periods, in PSC patients. Bezafibrate was prescribed at 200 mg b.i.d. The primary endpoint was defined as improvements in liver function test (LFT) data after bezafibrate treatment ... Please click here to read the remainder of the abstract.
Article first published online: 21 AUG 2015
DOI: 10.1002/jhbp.281
© 2015 Japanese Society of Hepato-Biliary-Pancreatic Surgery
Abstract
Background:
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease. Medical treatments must be devised to avoid or postpone liver transplantation in PSC patients. No clinical trial has prospectively explored the efficacy of bezafibrate in PSC patients.
Methods:
We conducted a prospective study of 12-week bezafibrate treatment, with pre- and post-treatment observation periods, in PSC patients. Bezafibrate was prescribed at 200 mg b.i.d. The primary endpoint was defined as improvements in liver function test (LFT) data after bezafibrate treatment ... Please click here to read the remainder of the abstract.
Article first published online: 21 AUG 2015
DOI: 10.1002/jhbp.281
© 2015 Japanese Society of Hepato-Biliary-Pancreatic Surgery
RSS Feed